

Online Resource 2

Table 2 Characteristics of excluded studies (n=27)

#	Author, year of publication	Reason for exclusion
1	Abdull et al. (2017) [1] ^a	Intervention not aimed at medicine use
2	Al-Saikhan (2015) [2]	Not RCT, NRCT, CBA or ITS
3	Andrew (2001) [3]	Full text could not be obtained, no author contact information listed
4	Anonymous (2009) [4]	No intervention (commentary or brief view)
5	Anonymous (2011) [5]	No intervention (commentary or brief view)
6	Anonymous (2011) [6]	No intervention (commentary or brief view)
7	Berthenet (2013) [7] ^a	Participants not visually impaired
8	Davis et al. (2012) [8]	Participants not visually impaired
9	Doughty (1997) [9]	No intervention (review on ophthalmic medicines)
10	Easley et al. (2017) [10]	No intervention (qualitative study)
11	Edmunds et al. (1997) [11]	Participants not visually impaired
12	Hill (2013) [12] ^a	Intervention not aimed at medicine use
13	Honrubia (2012) [13] ^a	The registered trial is not published. It examines adherence using electronic adherence monitoring device. Not clear if pharmacists are involved
14	Layangool (2017) [14] ^a	Intervention not aimed at medicine use
15	Leat et al. (2016) [15]	Not RCT, NRCT, CBA or ITS
16	Manning et al. (2007) [16]	Participants not visually impaired
17	Muchart (2005) [17] ^a	Full text could not be obtained
18	O'Hare et al. (2009) [18] ^a	No intervention (cross-sectional study)
19	Panos (2011) [19]	No intervention (commentary or brief view)
20	Philpott (2103) [20]	No intervention (commentary or brief view)
21	Philpott (2014) [21]	No intervention (commentary or brief view)
22	Rees et al. (2015) [22] ^a	Intervention not aimed at medicine use
23	Stegemann (2014) [23]	No intervention (commentary or brief view)
24	Tandy and Bamford (2010) [24]	No intervention (review on medication compliance aids)
25	Waterman et al. (2018) [25] ^a	Intervention not delivered by pharmacists
26	Wolinsky (2006) [26]	No intervention (commentary or brief view)
27	Zagaria (2007) [27]	No intervention (commentary or brief view)

^a Studies from trial registries and grey literature

References to studies excluded from this review

1. Abdull MM, McCambridge J, Evans J, Muazu F, Gilbert C. Can adapted motivational interviewing improve uptake of surgical or laser treatment for glaucoma in Nigeria: randomized controlled trial. *J Glaucoma*. 2017;26(9):822-8.
2. Al-Saikhani FI. Clinical pharmacy experience in ophthalmology setting of using collaborative drug therapy management (CDTM). *Eur J Hosp Pharm*. 2015;22(6):347-52.
3. Andrew S. The ophthalmic pharmacist as part of a multidisciplinary team. *Hospital Pharmacist*. 2001;8(3):75-6.
4. Anonymous. Correct counseling: Correct application of eye medicines - A problem! *Dtsch Apoth Ztg*. 2009;149(15):68-9.
5. Anonymous. Labelling remains a concern. *Pharmacy News*. 2011:15-.
6. Anonymous. Safety manage medicines for the visually impaired. *AJP*. 2011;92(1090):28.
7. Berthenet M. *Validation of pictograms depicting medication instructions in the elderly population [PhD Thesis]*. France: Faculty of Pharmacy, Claude Bernard University Lyon; 2013.
8. Davis CR, Toll EC, Bevis PM, Burden HP. Improving patient safety through education: how visual recognition skills may reduce medication errors on surgical wards. *Nurs Rep*. 2012;2(1):1-3.
9. Doughty MJ. A guide to ophthalmic pharmacy medicines in the United Kingdom. *Ophthalmic Physiol Opt*. 1997;17(SUPPL. 1):S2-S8.
10. Easley W, Kuber R, Ozok AA. An empirical study examining medication management among individuals with visual impairments. *Univ Access Inf Soc*. 2016;16(2):483-95.
11. Edmunds B, Francis PJ, Elkington AR. Communication and compliance in eye casualty. *Eye*. 1997;11(3):345-8.
12. Hill K. Effectiveness of vision intervention, environmental modification, and staff training targeting vision factors; to improve vision, independence, safety and quality of life in the residential care setting. Australian New Zealand Clinical Trials Registry. 2013. <https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=83100>. Accessed 15 Jun 2018.
13. Honrubia FM. Adherence of patients using travalert® for instillation of a fixed combination of travoprost 0.004%/timolol 0.5% compared to a concomitant regimen of travoprost 0.004% and timolol 0.5%. *ClinicalTrials.gov*. 2012. <https://clinicaltrials.gov/ct2/show/record/NCT00508469?view=record>. Accessed 20 Jun 2018.
14. Layangool T. Quality of life of low vision patients and outcome of low-vision rehabilitation in Siriraj hospital. International Clinical Trials Registry Platform. 2017. <http://apps.who.int/trialsearch/Trial2.aspx?TrialID=TCTR20171013002>. Accessed 19 Jun 2018.
15. Leat SJ, Krishnamoorthy A, Carbonara A, Gold D, Rojas-Fernandez C. Improving the legibility of prescription medication labels for older adults and adults with visual impairment. *Can Pharm J*. 2016;149(3):174-84.
16. Manning DM, O'Meara JG, Williams AR, Rahman A, Myhre D, Tammel KJ et al. 3D: a tool for medication discharge education. *Quality Saf Health Care*. 2007;16(1):71-6.
17. Muchart B. *Low-vision rehabilitation by a specialized center [PhD Thesis]*. France: Ophthalmology, University of Angers; 2005.
18. O'Hare F, Jegathan VS, Rokahr CG, Rogers SL, Crowston JG. Readability of prescription labels and medication recall in a population of tertiary referral glaucoma patients. *Clin Exp Ophthalmol*. 2009;37(9):849-54.
19. Panos A. The \$290 billion pharmacy problem. *Drug Topics*. 2011;155(8):8.
20. Philpott L. Eye wise. *AJP*. 2013;94(1121):46-50.
21. Philpott L. Helping customers: See clearly. *AJP*. 2014;95(1333):43-7.

22. Rees G, Xie J, Chiang PP, Larizza MF, Marella M, Hassell JB et al. A randomised controlled trial of a self-management programme for low vision implemented in low vision rehabilitation services. *Patient Educ Couns*. 2015;98(2):174-81.
23. Stegemann S. Meeting an aging population's evolving needs. *Contract Pharma*. 2014(5).
24. Tandy C, Bamford L. Medication compliance aids. *Eur Geriatr Med*. 2010;1(5):314-6.
25. Waterman H, Bull S, Shaw M, Richardson C. Group-based patient education delivered by nurses to meet a clinical standard for glaucoma information provision: the G-TRAIN feasibility study. *Pilot Feasibility Stud*. 2018;4:121. doi:10.1186/s40814-018-0313-5.
26. Wolinsky H. Tagging products and people. Despite much controversy, radiofrequency identification chips have great potential in healthcare. *EMBO Rep*. 2006;7(10):965-8.
27. Zagaria MAE. Vision, cognition, and mobility challenges for elderly drivers. *US Pharm*. 2007;32(1):36-40.